Literature DB >> 33492655

Sotalol does not interfere with the antielectroshock action of selected second-generation antiepileptic drugs in mice.

Kinga K Borowicz-Reutt1, Monika Banach2, Monika Rudkowska2, Anna Stachniuk3.   

Abstract

BACKGROUND: Due to blocking β-receptors, and potassium KCNH2 channels, sotalol may influence seizure phenomena. In the previous study, we have shown that sotalol potentiated the antielectroshock action of phenytoin and valproate in mice.
MATERIALS AND METHODS: As a continuation of previous experiments, we examined the effect of sotalol on the action of four chosen second-generation antiepileptic drugs (oxcarbazepine, lamotrigine, pregabalin, and topiramate) against the maximal electroshock in mice. Undesired effects were evaluated in the chimney test (motor impairment) and step-through passive-avoidance task (long-term memory deficits). Finally, brain concentrations of antiepileptics were determined by fluorescence polarization immunoassay, while those of sotalol by liquid chromatography-mass spectrometry.
RESULTS: Sotalol at doses of up to 100 mg/kg did not affect the electroconvulsive threshold. Applied at doses of 80-100 mg/kg, sotalol did not affect the antielectroshock action of oxcarbazepine, lamotrigine, pregabalin, or topiramate. Sotalol alone and in combinations with antiepileptics impaired neither motor performance nor long-term memory. Finally, sotalol significantly decreased the brain concentrations of lamotrigine and increased those of oxcarbazepine and topiramate. Pharmacokinetic interactions, however, did not influence the final antielectroshock effects of above-mentioned drug combinations. On the other hand, the brain concentrations of sotalol were not changed by second-generation antiepileptics used in this study.
CONCLUSION: Sotalol did not reduce the antielectroshock action of four second-generation antiepileptic drugs examined in this study. Therefore, this antidepressant drug should not interfere with antiseizure effects of lamotrigine, oxcarbazepine, pregabalin, and topiramate in patients with epilepsy. To draw final conclusions, our preclinical data should still be confirmed in other experimental models and clinical conditions.

Entities:  

Keywords:  Electroshock maximal; Pharmacodynamic interactions; Pharmacokinetic interactions; Second-generation antiepileptic drugs; Sotalol

Year:  2021        PMID: 33492655      PMCID: PMC7994213          DOI: 10.1007/s43440-020-00210-2

Source DB:  PubMed          Journal:  Pharmacol Rep        ISSN: 1734-1140            Impact factor:   3.024


  31 in total

1.  The maximal electroshock seizure (MES) model in the preclinical assessment of potential new antiepileptic drugs.

Authors:  M M Castel-Branco; G L Alves; I V Figueiredo; A C Falcão; M M Caramona
Journal:  Methods Find Exp Clin Pharmacol       Date:  2009-03

2.  Effect of beta-adrenoceptor antagonists and some related drugs on maximal electroshock seizures in mice.

Authors:  N Khanna; A Ray; M Alkondon; P Sen
Journal:  Indian J Exp Biol       Date:  1989-02       Impact factor: 0.818

Review 3.  Neuro-arrhythmology: a challenging field of action and research: a review from the Task Force of Neuro-arrhythmology of Italian Association of Arrhythmias and Cardiac Pacing.

Authors:  Stefano Strano; Danilo Toni; Fabrizio Ammirati; Tommaso Sanna; Marco Tomaino; Michele Brignole; Andrea Mazza; Bich L Nguyen; Carlo Di Bonaventura; Renato P Ricci; Giuseppe Boriani
Journal:  J Cardiovasc Med (Hagerstown)       Date:  2019-11       Impact factor: 2.160

4.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.

Authors:  Paulus Kirchhof; Stefano Benussi; Dipak Kotecha; Anders Ahlsson; Dan Atar; Barbara Casadei; Manuel Castella; Hans-Christoph Diener; Hein Heidbuchel; Jeroen Hendriks; Gerhard Hindricks; Antonis S Manolis; Jonas Oldgren; Bogdan Alexandru Popescu; Ulrich Schotten; Bart Van Putte; Panagiotis Vardas
Journal:  Eur Heart J       Date:  2016-08-27       Impact factor: 29.983

5.  Antiarrhythmic drugs-clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP).

Authors:  Gheorghe-Andrei Dan; Antoni Martinez-Rubio; Stefan Agewall; Giuseppe Boriani; Martin Borggrefe; Fiorenzo Gaita; Isabelle van Gelder; Bulent Gorenek; Juan Carlos Kaski; Keld Kjeldsen; Gregory Y H Lip; Bela Merkely; Ken Okumura; Jonathan P Piccini; Tatjana Potpara; Birgitte Klindt Poulsen; Magdi Saba; Irina Savelieva; Juan L Tamargo; Christian Wolpert
Journal:  Europace       Date:  2018-05-01       Impact factor: 5.214

Review 6.  Comorbidity between epilepsy and cardiac arrhythmias: Implication for treatment.

Authors:  Gaetano Zaccara; Simona Lattanzi
Journal:  Epilepsy Behav       Date:  2019-07-03       Impact factor: 2.937

7.  Dose translation from animal to human studies revisited.

Authors:  Shannon Reagan-Shaw; Minakshi Nihal; Nihal Ahmad
Journal:  FASEB J       Date:  2007-10-17       Impact factor: 5.191

Review 8.  Sotalol.

Authors:  John Alvin Kpaeyeh; John Marcus Wharton
Journal:  Card Electrophysiol Clin       Date:  2016-06

9.  Are women more susceptible than men to drug-induced QT prolongation? Concentration-QTc modelling in a phase 1 study with oral rac-sotalol.

Authors:  Borje Darpo; Dilip R Karnad; Fabio Badilini; Jeff Florian; Christine E Garnett; Snehal Kothari; Gopi Krishna Panicker; Nenad Sarapa
Journal:  Br J Clin Pharmacol       Date:  2014-03       Impact factor: 4.335

10.  Nebivolol attenuates the anticonvulsant action of carbamazepine and phenobarbital against the maximal electroshock-induced seizures in mice.

Authors:  Kinga K Borowicz-Reutt; Monika Banach; Monika Rudkowska
Journal:  Pharmacol Rep       Date:  2019-12-20       Impact factor: 3.024

View more
  1 in total

Review 1.  Effects of Antiarrhythmic Drugs on Antiepileptic Drug Action-A Critical Review of Experimental Findings.

Authors:  Kinga K Borowicz-Reutt
Journal:  Int J Mol Sci       Date:  2022-03-07       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.